Payment overview · 2025
General Payments
$17,552.89
94 reported records · 16 companies
Healthcare provider profile · identity verified
Olatunde Osofisan, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · BROOKLYN, NY · NPI 1306129341
Verified facts
What the public records show
CMS Open Payments records show Olatunde Osofisan, DPM received $17,552.89 in general payments during 2025 across 94 reported records.
Novastep Inc. accounted for 38.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novastep Inc. | Unresolved — no canonical attribution shown | $6,693.81 | 38.1% | 2 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $2,621.92 | 14.9% | 12 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $2,263.54 | 12.9% | 26 | 2025 |
| ACUMED LLC | Unresolved — no canonical attribution shown | $2,074.65 | 11.8% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,095.72 | 6.2% | 8 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $728.60 | 4.2% | 9 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $524.15 | 3.0% | 4 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $510.95 | 2.9% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $366.45 | 2.1% | 2 | 2025 |
| DJO, LLC | Unresolved — no canonical attribution shown | $243.25 | 1.4% | 5 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $157.58 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$110.34 | 0.6% | 2 | 2025 |
| LifeNet Health | Unresolved — no canonical attribution shown | $67.69 | 0.4% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $59.24 | 0.3% | 3 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $20.52 | 0.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $14.48 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $7,940.01 | 84 |
| Royalty or License | $6,693.81 | 2 |
| Travel and Lodging | $2,919.07 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARCAD Normalized: arcad |
Device | Novastep Inc. | $6,693.81 | 2 | 2025 |
Source payment records
|
|||||
| Acumed Normalized: acumed |
Device | ACUMED LLC | $2,049.89 | 11 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $1,191.03 | 4 | 2025 |
Source payment records
|
|||||
| OsteoMed Normalized: osteomed |
Device | ACUMED LLC | $972.46 | 6 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY Normalized: lapiplasty |
Device | TREACE MEDICAL CONCEPTS, INC. | $679.82 | 2 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $587.80 | 5 | 2025 |
Source payment records
|
|||||
| VITOSS Normalized: vitoss |
Device | Stryker Corporation | $574.61 | 4 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $510.95 | 4 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $397.39 | 3 | 2025 |
Source payment records
|
|||||
| CITREFIX Normalized: citrefix |
Device | Stryker Corporation | $383.52 | 4 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $366.50 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $366.45 | 2 | 2025 |
Source payment records
|
|||||
| ACTISHIELD Normalized: actishield |
Device | Stryker Corporation | $292.95 | 4 | 2025 |
Source payment records
|
|||||
| FIXOS Normalized: fixos |
Device | Stryker Corporation | $292.48 | 2 | 2025 |
Source payment records
|
|||||
| ALLOWRAP Normalized: allowrap |
Device | Stryker Corporation | $281.64 | 2 | 2025 |
Source payment records
|
|||||
| COLINK PLATING SYSTEM Normalized: colink plating system |
Device | Linvatec Corporation | $252.15 | 2 | 2025 |
Source payment records
|
|||||
| CMF Normalized: cmf |
Device | DJO, LLC | $243.25 | 5 | 2025 |
Source payment records
|
|||||
| 7 X 23MM CITRELOCK IMPLANT Normalized: 7 x 23mm citrelock implant |
Device | Stryker Corporation | $236.40 | 3 | 2025 |
Source payment records
|
|||||
| SONICANCHOR Normalized: sonicanchor |
Device | Stryker Corporation | $210.78 | 2 | 2025 |
Source payment records
|
|||||
| VALOR Normalized: valor |
Device | Stryker Corporation | $186.53 | 2 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $169.98 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $169.56 | 1 | 2025 |
Source payment records
|
|||||
| CHARLOTTE Normalized: charlotte |
Device | Stryker Corporation | $169.39 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $157.58 | 1 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $148.52 | 1 | 2025 |
Source payment records
|
|||||
| ASNIS Normalized: asnis |
Device | Stryker Corporation | $148.35 | 1 | 2025 |
Source payment records
|
|||||
| PANGEA Normalized: pangea |
Device | Stryker Corporation | $148.00 | 1 | 2025 |
Source payment records
|
|||||
| INnate Implant Normalized: innate implant |
Device | ACUMED LLC | $141.99 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $141.88 | 1 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $141.69 | 2 | 2025 |
Source payment records
|
|||||
| IGNITE Normalized: ignite |
Device | Stryker Corporation | $137.05 | 1 | 2025 |
Source payment records
|
|||||
| T2 Normalized: t2 |
Device | Stryker Corporation | $131.45 | 1 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $120.09 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 3DI Normalized: ortholoc 3di |
Device | Stryker Corporation | $118.98 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $118.28 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $110.34 | 2 | 2025 |
Source payment records
|
|||||
| FRACTURE AND CORRECTION COLAG 2 Normalized: fracture and correction colag 2 |
Device | Linvatec Corporation | $94.50 | 1 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $93.71 | 2 | 2025 |
Source payment records
|
|||||
| SALVATION Normalized: salvation |
Device | Stryker Corporation | $84.66 | 2 | 2025 |
Source payment records
|
|||||
| GRAVITY SYNCHFIX Normalized: gravity synchfix |
Device | Stryker Corporation | $72.12 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 2 LAPIFUSE Normalized: ortholoc 2 lapifuse |
Device | Stryker Corporation | $69.58 | 1 | 2025 |
Source payment records
|
|||||
| TheraGenesis Wound Matrix Normalized: theragenesis wound matrix |
Device | LifeNet Health | $67.69 | 2 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clobetasol Propionate | Clobetasol Propionate | 294 | 95 |
| Caspofungin Acetate | Caspofungin Acetate | 208 | 78 |
| Doxepin Hcl | Doxepin Hcl | 154 | 90 |
| Diflorasone Diacetate | Diflorasone Diacetate | 98 | 46 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 95 | 38 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 62 | 20 |
| Tavaborole | Tavaborole | 48 | 22 |
| Budesonide Er | Budesonide | 40 | 15 |
| Desoximetasone | Desoximetasone | 31 | 13 |
| Fluocinonide | Fluocinonide | 27 | 15 |
| Ammonium Lactate | Ammonium Lactate | 26 | 17 |
| Ertaczo | Sertaconazole Nitrate | 24 | 11 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 21 | 11 |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 21 | 13 |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 13 |
| Naproxen Sodium Er | Naproxen Sodium | 17 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 15 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,552.89 · 94 records | Novastep Inc. | 7 X 23MM CITRELOCK IMPLANT, ACTISHIELD, ACTIV.A.C., ALLOWRAP, APLIGRAF, ARCAD, ASNIS, AUGMENT INJECTABLE, AVEIR, Acumed, BIOBRACE 23MM, CHARLOTTE, CITREFIX, CLOSUREFAST, CMF, COLINK PLATING SYSTEM, CYGNUS DUAL, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ESPRIT, FIXOS, FRACTURE AND CORRECTION COLAG 2, GALLANT, GRAVITY SYNCHFIX, IGNITE, INnate Implant, LAPIPLASTY, LAPIPLASTY SYSTEM 1, NOVOSORB BTM, ORTHOLOC 2 LAPIFUSE, ORTHOLOC 3DI, OsteoMed, PANGEA, PROSTEP MICA, PURAPLY WOUND MATRIX, QUTENZA, SALVATION, SONICANCHOR, Senza, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, T2, TMC NANOPLASTY SYSTEM, TheraGenesis Wound Matrix, ULTREON, VALOR, VARIAX, VITOSS | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error